Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18985720 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | December 2024 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18812527 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | August 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18652993 | RAMIPRIL SOLUTION FOR ORAL DOSAGE | May 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18591969 | CRYSTALLINE SALTS OF PSILOCIN | February 2024 | March 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18591925 | CRYSTALLINE SALTS OF PSILOCIN | February 2024 | March 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18685899 | ABIRATERONE PRECURSOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2024 | June 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18529689 | TEAD INHIBITORS AND METHODS OF USES THEREOF | December 2023 | April 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18278628 | PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOF | October 2023 | June 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18480898 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18344336 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | June 2023 | August 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18344555 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | June 2023 | December 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18340006 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | June 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18337623 | PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUND | June 2023 | June 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18208025 | METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROME | June 2023 | October 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18202681 | SELECTIVE DETECTION OF BED BUGS | May 2023 | March 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18311126 | STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE | May 2023 | May 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18304270 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | April 2023 | February 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18300312 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | April 2023 | November 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18129267 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | March 2023 | April 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18128075 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | March 2023 | February 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18184618 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | March 2023 | July 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18160897 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | January 2023 | March 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18153954 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | January 2023 | January 2024 | Abandon | 12 | 0 | 1 | No | No |
| 18146698 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | December 2022 | November 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18146393 | COMPOSITIONS COMPRISING CAROTENOIDS, METHODS AND APPLICATION THEREOF | December 2022 | February 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18063695 | USE OF TETRANDRINE IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PNEUMOCONIOSIS | December 2022 | January 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18075163 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | December 2022 | September 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17992254 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | November 2022 | January 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17985740 | TREATING LIVER DISORDERS WITH AN SSAO INHIBITOR | November 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 17970933 | TOPICAL TRANEXAMIC ACID COMPOSITIONS AND METHODS OF USE THEREOF | October 2022 | March 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 17965569 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | October 2022 | November 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17915123 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | September 2022 | March 2025 | Allow | 29 | 3 | 1 | Yes | No |
| 17954319 | COMPOSITION FOR MODULATING HYDROGEN ION PHYSIOLOGY RELATED TO BRAIN HEALTH COMPONENT | September 2022 | August 2024 | Abandon | 23 | 2 | 1 | Yes | No |
| 17934625 | PYRIDAZINES | September 2022 | December 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17901775 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | September 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17818846 | CRYSTALLINE FORM OF TOLEBRUTINIB | August 2022 | March 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17807083 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | June 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17751998 | CRYSTALLINE SALTS OF PSILOCIN | May 2022 | December 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17752526 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | May 2022 | October 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17749082 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | May 2022 | August 2023 | Abandon | 15 | 2 | 0 | No | No |
| 17736773 | IMPROVING THE QUALITY OF HUMAN OOCYTES | May 2022 | August 2024 | Abandon | 27 | 2 | 1 | Yes | No |
| 17734601 | LSD AND PSILOCYBIN DOSE EQUIVALENCE DETERMINATION | May 2022 | April 2025 | Abandon | 36 | 3 | 1 | No | No |
| 17721789 | COMPOSITIONS AND METHODS FOR PROMOTING SLEEP | April 2022 | April 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17678990 | TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDES | February 2022 | May 2023 | Abandon | 15 | 2 | 0 | Yes | No |
| 17623477 | CAPACITATIVE CALCIUM ENTRY INHIBITORS | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17545864 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELL GROWTH | December 2021 | March 2024 | Allow | 27 | 4 | 0 | Yes | No |
| 17541035 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | December 2021 | May 2022 | Allow | 6 | 1 | 1 | No | No |
| 17540826 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | December 2021 | May 2023 | Allow | 17 | 3 | 1 | Yes | Yes |
| 17595772 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | November 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17515372 | METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUG | October 2021 | April 2024 | Abandon | 29 | 4 | 1 | Yes | No |
| 17607632 | METHODS OF TREATING PRURITUS | October 2021 | June 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17502559 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | October 2021 | September 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17604371 | COMBINATION THERAPY | October 2021 | December 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17503126 | LIQUID PHARMACEUTICAL COMPOSITIONS | October 2021 | January 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17488568 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | September 2021 | December 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17440879 | NOVEL AZAINDOLE DERIVATIVE | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17439611 | PKM2 MODULATORS AND METHODS FOR THEIR USE | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17472647 | Method For Treating COVID-19 and Related Viral Infections | September 2021 | December 2023 | Abandon | 27 | 2 | 1 | No | No |
| 17471922 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | September 2021 | June 2024 | Allow | 33 | 4 | 1 | Yes | No |
| 17469178 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | September 2021 | November 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17465394 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | September 2021 | July 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17409258 | A METHOD FOR IMPROVING ANTICANCER EFFECT OF AN ANTICANCER DRUG FOR TREATING OR PREVENTING CANCER | August 2021 | March 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17445483 | TREATMENT OF ENDOPLASMIC RETICULUM MEDIATED DISORDERS WITH ANILIDE DERIVATIVES | August 2021 | October 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17400164 | Synthesis of Anti-inflammatory and Anti-cancer Agents through Fungal Transformation of Mibolerone | August 2021 | June 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17429791 | PHARMACEUTICAL COMPOSITION FOR CO-ADMINISTRATION OF ACIDOSIS-INDUCING DRUG | August 2021 | May 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17427037 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS | July 2021 | January 2023 | Abandon | 17 | 0 | 0 | No | No |
| 17386339 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | July 2021 | August 2024 | Abandon | 37 | 3 | 0 | Yes | No |
| 17425629 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | July 2021 | May 2025 | Abandon | 45 | 4 | 1 | Yes | No |
| 17381308 | METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO HYDROGEN SULFIDE | July 2021 | November 2023 | Allow | 27 | 2 | 1 | Yes | No |
| 17365499 | Finished Pharmaceutical Dosage Form Of A Methenamine Salt Such As Methenamine Mandelate | July 2021 | January 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17361862 | METHOD TO PREVENT AND TREAT HEARING LOSS BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | June 2021 | January 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17362969 | Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep | June 2021 | October 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17360466 | METHOD TO PREVENT AND TREAT GINGIVAL RECESSION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | June 2021 | June 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17352737 | METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROME | June 2021 | November 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17416639 | COMPOUNDS AND METHODS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (PKD) | June 2021 | March 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17414335 | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17347272 | MEDICAMENT, COMPOUND, COMPOSITION AND METHOD FOR TREATING HERPES | June 2021 | July 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17339468 | SUPPLEMENT INCLUDING GAMMA-AMINOBUTYRIC ACID FOR RESTORING GROWTH HORMONE LEVELS | June 2021 | July 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17299844 | STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE | June 2021 | June 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17298115 | AGONISTS OF PPAR-delta | May 2021 | May 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17297848 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | May 2021 | October 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17303397 | SMALL MOLECULE ACTIVATORS OF POLYCYSTIN-2 (PKD2) AND USES THEREOF | May 2021 | March 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17296968 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17295638 | METHODS FOR MANAGEMENT OF WEIGHT | May 2021 | January 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17294793 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17320316 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | May 2021 | March 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17302777 | COMPOSITIONS FOR TREATING HAIR LOSS | May 2021 | August 2024 | Abandon | 40 | 3 | 1 | No | No |
| 17292403 | METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17307851 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | May 2021 | August 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17289123 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17285849 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity | April 2021 | April 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17232049 | NOVEL KV3 MODULATORS | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17284824 | ANTIPSYCHOTIC AND USE THEREOF | April 2021 | April 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17283700 | GLUCOCORTICOID RECEPTOR MODULATORS | April 2021 | October 2022 | Abandon | 19 | 0 | 1 | No | No |
| 17282401 | METHODS TO TREAT RENAL DISORDERS USING CALCIUM CHANNEL INHIBITORS | April 2021 | January 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17278880 | POLYMER-PARTICLE LIGHT-CLEAVABLE CARRIER SYSTEMS FOR PHOTODYNAMIC THERAPY | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17278103 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | March 2021 | August 2024 | Abandon | 41 | 4 | 1 | Yes | No |
| 17278051 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | March 2021 | January 2023 | Abandon | 22 | 1 | 1 | No | No |
| 17205451 | ANTIVIRAL COMPOUNDS AND METHOD FOR TREATING HEPATOTROPIC VIRAL INFECTION, PARTICULARLY HEPATITIS B AND HEPATITIS D | March 2021 | October 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17276543 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME | March 2021 | February 2025 | Allow | 47 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WELLS, LAUREN QUINLAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WELLS, LAUREN QUINLAN works in Art Unit 1622 and has examined 184 patent applications in our dataset. With an allowance rate of 35.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner WELLS, LAUREN QUINLAN's allowance rate of 35.3% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WELLS, LAUREN QUINLAN receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WELLS, LAUREN QUINLAN is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +61.3% benefit to allowance rate for applications examined by WELLS, LAUREN QUINLAN. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.5% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.